therapy

Where is ovarian cancer treatment headed? 1:12
Where is ovarian cancer treatment headed?
Domenica Lorusso
New potential applications for CAR T-cell therapy 2:14
New potential applications for CAR T-cell therapy
Howard Burris • 1 Jun 2018
PROSPECT: how effective is the new prostvac vaccine against prostate cancer? 5:54
PROSPECT: how effective is the new prostvac vaccine against prostate cancer?
James Gulley • 1 Jun 2018
Drugs with low response rates – should they always be offered to patients? 3:22
Drugs with low response rates – should they always be offered to patients?
Jacob Kettle • 21 Mar 2018
Proton beam therapy in the UK: usage and monitoring 1:54
Proton beam therapy in the UK: usage and monitoring
Anthony Zietman • 5 Nov 2017
Key messages on prostate cancer treatment from BOPA 2017 0:34
Key messages on prostate cancer treatment from BOPA 2017
Robert Jones • 6 Oct 2017
Improving radiation treatment using proton beam therapy 3:04
Improving radiation treatment using proton beam therapy
Anthony Zietman • 5 Nov 2017
Proton beam therapy for non-pediatric cancers: UK vs. US 5:53
Proton beam therapy for non-pediatric cancers: UK vs. US
Anthony Zietman • 5 Nov 2017
Rituximab and its biosimilars: consistencies and advantages 0:48
Rituximab and its biosimilars: consistencies and advantages
Wojciech Jurczak
PARP inhibitors: game-changers for ovarian cancer patients? 1:53
PARP inhibitors: game-changers for ovarian cancer patients?
Mansoor Mirza
The delivery of niraparib and rucaparib as ovarian cancer treatment options 1:44
The delivery of niraparib and rucaparib as ovarian cancer treatment options
Mansoor Mirza
ESMO’s scientific value for gynecologic oncology 0:50
ESMO’s scientific value for gynecologic oncology
Mansoor Mirza
Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS 1:36
Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS
Robin Jones
Managing the side effects of immunotherapy: a vital consideration 3:01
Managing the side effects of immunotherapy: a vital consideration
Paolo Ascierto
Critical data points in the production of biosimilars 1:05
Critical data points in the production of biosimilars
Richard Markus
What can biosimilars offer us? 0:32
What can biosimilars offer us?
Richard Markus
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals